Tharimmune Announces 1-for-15 Reverse Stock Split [Yahoo! Finance]
Tharimmune, Inc. (THAR)
Company Research
Source: Yahoo! Finance
developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock after the close of trading on The Nasdaq Capital Market ("Nasdaq") on May 24, 2024. Tharimmune's common stock will trade on a post-split basis when the market opens on May 28, 2024 under the existing trading symbol "THAR" and the new CUSIP number 432705309. The reverse stock split was approved by Tharimmune stockholders at the Annual Meeting of Stockholders held on May 14, 2024, with the final ratio determined by the Company's Board of Directors. As a result of the reverse stock split, every 15 shares of issued and outstanding common stock will be exchanged for 1 share of common stock, with any fractional shares being rounded up to the next higher whole share. Immediately after the reverse stock split becomes effective, the Company will have approximately 785,978 shares of common stock
Show less
Read more
Impact Snapshot
Event Time:
THAR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
THAR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
THAR alerts
High impacting Tharimmune, Inc. news events
Weekly update
A roundup of the hottest topics
THAR
News
- Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of InfliximabAccesswire
- Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory BoardAccesswire
- Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor [Yahoo! Finance]Yahoo! Finance
- Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic AdvisorAccesswire
- Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104Accesswire
THAR
Sec Filings
- 9/16/24 - Form 8-K
- 8/12/24 - Form 4
- 8/12/24 - Form 4
- THAR's page on the SEC website